NCT05992597View on ClinicalTrials.gov

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2026

Conditions
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Interventions
DRUG

ZR2 RDHAP

ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER